Mitotane, sold under the brand name Lysodren, is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. It is a derivative of the early insecticide DDT and an isomer of p,p'-DDD (4,4'-dichlorodiphenyldichloroethane) and is also known as 2,4'-(dichlorodiphenyl)-2,2-dichloroethane (o,p'-DDD).

Market Analysis and Insights: Global Mitotane Market
The global Mitotane market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Mitotane Scope and Market Size
The global Mitotane market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mitotane market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Tablet
Capsule

Segment by Application
Adrenal Cortical Carcinoma
Cushing's Syndrome

The Mitotane market is analysed and market size information is provided by regions (countries). Segment by Application, the Mitotane market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Bristol Meyers Squibb
HRA Pharma